The Rabbit Polyclonal anti-ASAH1 antibody has been validated for WB, ELISA, IHC (p) and IF. It is suitable to detect ASAH1 in samples from Human, Mouse and Rat.
Catalog No. ABIN6990953
Quick Overview for ASAH1 antibody (C-Term) (ABIN6990953)
ASAH1 Antibody is affinity chromatography purified via peptide column.
Immunogen
ASAH1 antibody was raised against a 16 amino acid synthetic peptide near the carboxy terminus of the human ASAH1. The immunogen is located within amino acids 240 - 290 of ASAH1.
ASAH1 antibody can be used for detection of ASAH1 by Western blot at 1 and 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human and rat samples and Immunofluorescence in human and rat samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
ASAH1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
ASAH1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
ASAH1 Antibody: Sphingolipids are hydrolyzed by ceramidases to yield sphingosine and fatty acids. These ceramidases are classified according to the pH range that supports their optimal activity. ASAH1 is an acid ceramidase and key regulator of ceramide metabolism. Mutations in this gene results in Farber Lipogranulomatosis, a fatal human genetic disorder that results in the painful swelling of the joints and tendons and pulminary insufficiency, while a complete knockout of its expression is lethal in mice. Recent studies have shown elevated levels of ASAH1 in Alzheimer's disease (AD) patients correlating with a reduction in sphingomyelin and elevation of ceramide. Pretreatment of cultured neurons with recombinant AHAH1 prevented the cells from undergoing A-beta (Ab)-induced apoptosis.